(Q45300446)

11 December 2017

title

Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease (English)

1 reference

11 December 2017

0 references

5

1 reference

11 December 2017

8

G D Pearlson

1 reference

11 December 2017

E H Aylward

1

1 reference

11 December 2017

A M Codori

2

1 reference

11 December 2017

A Rosenblatt

3

1 reference

11 December 2017

M Sherr

4

1 reference

11 December 2017

O C Stine

6

1 reference

11 December 2017

P E Barta

7

1 reference

11 December 2017

C A Ross

9

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

11 December 2017

1 reference

11 December 2017

volume

15

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

552-560

1 reference

Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA).

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Cerebral structure on MRI, part II: Specific changes in Alzheimer's and Huntington's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Positron emission tomography in the early diagnosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

[11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Basal ganglia volume and proximity to onset in presymptomatic Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Longitudinal change in basal ganglia volume in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Unified Huntington's disease rating scale: a follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Functional decline in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Huntington disease: Clinical care and evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Trinucleotide repeat length and clinical progression in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Evoked potentials in Huntington's disease. A comparative and longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Experimental therapeutics of neurodegenerative disorders: unmet needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

A controlled clinical trial of baclofen as protective therapy in early Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Assessment of coenzyme Q10 tolerability in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

The diagnosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

CAG repeat number governs the development rate of pathology in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Does CAG repeat number predict the rate of pathological changes in Huntington's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Unified Huntington's disease rating scale: Reliability and consistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200005%2915%3A3%3C552%3A%3AAID-MDS1020%3E3.0.CO%3B2-P

10.1002/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference